ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer
November 10, 2018CPC634 is a new drug modality. It combines CriPec® nanoparticles with docetaxel (Taxotere®), a clinically validated chemotherapy, as its therapeutic payload. This nanomedicine candidate has been designed to enable enhanced tumour accumulation and localise -
Cristal Therapeutics Awarded €2.5 Million Horizon 2020 Grant to Advance Its CriPec®-docetaxel Throug
November 30, 2017CriPec -docetaxel is a new drug mode. Docetaxel, a clinically proven chemotherapy drug (trade name Taxotere), is used as a therapeutic payload into nanoparticles.
Pharma Sources Insight January 2025
